Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 399.29M |
| Revenue (ttm) | 5.85M |
| Net Income (ttm) | -49.68M |
| Shares Out | 168.42M |
| EPS (ttm) | -0.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,025,973 |
| Open | 2.38 |
| Previous Close | 2.38 |
| Day's Range | 2.27 - 2.38 |
| 52-Week Range | 0.65 - 4.26 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+204.3%) |
| Est. Earnings Date | Dec 22, 2021 |
About OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLex...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 204.35% from the latest price.
News
Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET Live fireside chat with C. Russell Trenary, President and CEO of Outlook Ther...
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETIN...
ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev...
Outlook Therapeutics: Q3 Earnings Insights
Shares of Outlook Therapeutics (NASDAQ:OTLK) moved higher by 2.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 133.33% year over year to ($...
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
ISELIN, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
ISELIN, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Are Penny Stocks Worth It? 3 to Watch This Week
Trading penny stocks is more popular than ever; here's 3 you need to know about The post Are Penny Stocks Worth It? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Informatio...
7 Penny Stocks That Have That ‘Get Rich' Potential
If you want to travel on the speculative side of the market, these penny stocks might have the right stuff for you to strike it rich. The post 7 Penny Stocks That Have That ‘Get Rich' Potential appeared...
Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now
Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...
Why Outlook Therapeutics Stock Surged Today
Investors are excited about the potential of the drugmaker's experimental wet AMD treatment.
HC Wainwright Raises Price Target On Outlook Therapeutics After Wet AMD Trial Data
H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company announced "exceptionally strong" data that showed Lytenava's stat...
OTLK Stock: The Huge Trial News Lifting Outlook Therapeutics
OTLK stock is on the move today. The company is coming forth with promising data on its treatment of a damaging eye disease.
Outlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients
Outlook Therapeutics Inc (NASDAQ: OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial evaluating ONS-5010 / LYTENAVA (bevacizumab) fo...
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYT...
ISELIN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
ISELIN, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva...
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
ISELIN, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulatio...
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
ISELIN, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulatio...
Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA...
ISELIN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation...
Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
ISELIN, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation...
Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
Live video webcast with Outlook Therapeutics' management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ET Live video webcast with Outlook Therapeutics' management team and k...
Hot Penny Stocks to Buy? 3 Stocks You Should Know About
Penny stocks are ready for a new month; should you watch these 3? The post Hot Penny Stocks to Buy?
Outlook Therapeutics is bringing a treatment for retinal disease to the market at the right time
There is something uniquely exciting about being the first company to bring a much-needed product to market. Outlook Therapeutics Inc (NASDAQ:OTLK) is hoping to become the first and only company to comm...
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA...
MONMOUTH JUNCTION, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formul...
Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
MONMOUTH JUNCTION, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmi...
Why Bausch Health, Oncolytics Biotech, And More Are Moving Today
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines ...